Hemispherx BioPharma (NYSEAMERICAN:HEB) Stock Price Up 21.8%

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) shares rose 21.8% during trading on Wednesday . The company traded as high as $7.50 and last traded at $6.76. Approximately 1,155,079 shares were traded during mid-day trading, an increase of 1,317% from the average daily volume of 81,539 shares. The stock had previously closed at $5.55.

Separately, Ascendiant Capital Markets set a $44.00 price objective on Hemispherx BioPharma and gave the company a “buy” rating in a report on Friday, May 17th.

Hemispherx BioPharma (NYSEAMERICAN:HEB) last released its quarterly earnings data on Thursday, May 16th. The specialty pharmaceutical company reported ($3.08) EPS for the quarter.

COPYRIGHT VIOLATION NOTICE: “Hemispherx BioPharma (NYSEAMERICAN:HEB) Stock Price Up 21.8%” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/06/12/hemispherx-biopharma-nyseamericanheb-stock-price-up-21-8.html.

About Hemispherx BioPharma (NYSEAMERICAN:HEB)

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Read More: Analyzing a company’s cash flow statement

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.